Tumor-associated antigen, mostly high molecular weight of glycolipids or glycoproteins. These tumor-associated antigen in the serum can be detected, many clinicians as the use of serum tumor markers.
Gastric tumor markers include:
CEA present in the gastrointestinal mucosa of embryonic cell with a number of malignant cells on the surface, is a glycoprotein. CEA increase can be found in colon cancer, gastric cancer, pancreatic cancer, breast cancer, lung cancer, medullary thyroid cancer and certain non-cancer diseases. Therefore, CEA-specific diagnosis of the poor. After the surgery 2-4 weeks to start checking on a regular basis, contribute to the analysis of the effect, determine recurrence and metastasis.
CA19-9 is a single-acid saliva gangliosides, is a high molecular weight glycoprotein. In a variety of adenocarcinoma of serum CA19-9 levels. Of pancreatic cancer, stomach cancer and liver bile duct high sensitivity. Joint determination of serum CA19-9 and CEA, gastric cancer screening can increase the sensitivity and specificity.
CA50 and CA19-9 similar to those that can be used to monitor the progress of the period of gastrointestinal and pancreatic cancer, but more specific CAl9-9 difference.
CA72-4 is a high molecular weight of the mucin-type elements. Can be used for diagnosis and monitoring of gastric cancer.
CAl95 is a glycoprotein, or mucin. In gastrointestinal cancer and pancreatic cancer patients with elevated levels of serum CAl95, it can be used as serum tumor markers of gastric cancer.
CA242 is a sticky protein. CA242 in the normal pancreas, colon exist, but the low level of expression; in pancreatic cancer, colon cancer, rectal and stomach cancer in high-level expression. CA242 diagnosis of gastric cancer and the sensitivity of CEA and similar CAl9-9.
CYFRA2H is a cytokeratin, it is normal and malignant cells, epithelial cells of the protein scaffold. When the abdominal cavity of gastric cancer metastasis, liver metastasis, and so on, CYFRA2H serum levels.Therefore, CYFRA2H gastric cancer is the progress or recurrence of reliable serum tumor markers.
How to treat gastric cancer serum tumor markers
1 comprehensive judgments
As the signs of gastric tumor sensitivity and specificity are limited, it can not be diagnosed as a tumor only basis. Their test results with the patient’s symptoms, signs, endoscopy, X-ray, ultrasound and cell or tissue pathology and other diagnostic results of the summary, comprehensive judgments.
2 the scope of application
A variety of gastric cancer tumor markers are not applicable to check large-scale population census. Combination of clinical symptoms and signs of serum tumor markers can choose items screening. In addition, by measuring serum tumor markers can be analyzed course, to monitor the recurrence or metastasis, treatment and prognosis.
In order to increase the sensitivity of gastric cancer diagnosis, at the same time can choose 2-3 specific high serum tumor marker for determination of the project, as long as there is a positive, can be judged as positive, which can increase the rate of positive diagnosis. At the same time improve the sensitivity, specific attention should be paid to lower, so the joint selection of targets, we must seriously.
4 quality control
Reagents for laboratory testing and the determination to have quality control measures. Otherwise, the test results unreliable, will reduce its clinical value.